Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Pemvidutide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune Completes $75M Common Stock Offering
    Altimmune Completes $75M Common Stock Offering

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229184/0/en/Altimmune-Announces-Closing-of-75-Million-Registered-Direct-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH
    Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212638/0/en/Altimmune-Receives-FDA-Breakthrough-Therapy-Designation-for-Pemvidutide-in-MASH.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Altimmune eyes phase 3 MASH trial as weight loss deepens
    Altimmune eyes phase 3 MASH trial as weight loss deepens

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208385/0/en/Altimmune-Announces-that-Pemvidutide-Achieved-Key-Measures-of-Success-at-48-Weeks-in-IMPACT-Phase-2b-MASH-Trial.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb

    13 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/altimmune-poised-for-1b-opportunity-as-mash-drug-aces-phase-iib

    BIOSPACE
    13 Nov 2025
    Share Share
    Altimmune Announces Publication of IMPACT Phase 2b Trial Data
    Altimmune Announces Publication of IMPACT Phase 2b Trial Data

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185445/0/en/Altimmune-Announces-Publication-of-IMPACT-Phase-2b-Trial-Data-in-The-Lancet-and-Concurrent-Late-Breaking-Oral-Presentation-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183618/0/en/Altimmune-Presents-AI-Based-Analysis-of-Liver-Fibrosis-Reduction-from-IMPACT-Phase-2b-Trial-of-Pemvidutide-in-MASH-in-Late-breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.